GBI Research

At GBI Research, we leverage extensive proprietary databases and employ novel data interrogation methodologies to generate new and meaningful analyses and insights.Our content and coverage are informed by close collaboration with a global network of domain-specific external partners; this allows us to deliver novel, thought-provoking and idea-generating insights that clients would normally struggle to access.Our in-house team of researchers and analysts – typically with MBAs, PhDs and MScs, as well as considerable healthcare industry experience is located across the UK, US and Asia Pacific. The team provides expert and insightful commentary to support evidence-based analyses of established and emerging markets.

All articles by GBI Research

  1. Waste not, want not: how exosomes went from trash to trials

    Exosomes are cell-derived vesicles that are present in almost all eukaryotic fluids, including blood, urine, cerebrospinal fluid (CSF) and cultured…
    Read More…

    6 Nov
  2. Does psychedelic microdosing have true potential in mental health?

    Micro-dosing is a growing health phenomenon involving the regular consumption of small doses of psychedelic drugs, usually a tenth of…
    Read More…

    31 Oct
  3. Xofluza: prospects for the first FDA-approved flu therapy in 20 years

    On October 20 2018, Xofluza (baloxavir marboxil) became the first medicine to achieve FDA approval for the treatment of the…
    Read More…

    31 Oct
  4. Will biosimilar launches send Humira tumbling in Europe?

    Last week, the EU saw the launch of four different biosimilars of Humira (adalimumab), the best-selling prescription drug in the…
    Read More…

    30 Oct
  5. The cancer immunotherapy market is growing fast

    Image Credit: Guido4. The number of companies generating significant revenue from immunotherapies for the treatment of cancer is expected to…
    Read More…

    30 Oct
  6. ADA-SCID: 40 years of research set for valuation

    David Vetter was born on 21 September 1971 via caesarean section in an operating theatre that had been deep-cleaned for…
    Read More…

    30 Oct
  7. Challenging the top-seller: the first Humira biosimilars have arrived

    The initial approval of AbbVie’s anti-inflammatory drug Humira was for the treatment of rheumatoid arthritis, but it has subsequently been…
    Read More…

    29 Oct
  8. Drugs and celery: how genetic engineering can resolve deadly interaction

    For centuries, celery has been consumed by people all over the world and is a popular ingredient in various cuisines….
    Read More…

    22 Oct
  9. Promising therapies in the breast cancer pipeline

    Breast cancer is one of the most common forms of cancer worldwide, with approximately 5.4 million cases worldwide in 2016….
    Read More…

    10 Oct
  10. Modest growth expected in Asia-Pacific heart failure therapeutics market

    The Asia-Pacific market for heart failure therapeutics was estimated at $733.7 million in 2017 and is projected to reach $1,435.9…
    Read More…

    5 Oct